Skip to content
Accessibility help

Search NICE…

Skip to content

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE

Search results

Skip to results

Type

TypeGuidance (59)Research recommendations (2)

Status

StatusAwaiting development (1)Discontinued (10)In development (9)Published (38)

Last updated

Last updatedLast 3 months (0)Last 6 months (1)Last year (3)Last 3 years (11)

Guidance programme

Guidance programmeClinical guidelines (2)NICE guidelines (2)Technology appraisal guidance (57)

Showing 61 to 61 of 61 results for ipilimumab

Sort by

Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]
In development Reference number: GID-TA11433 Expected publication date: TBC
Result type
Technology appraisal guidance
Status
In development

Previous page
1
3
4
Current page 5
Page 5 of 5

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS) Clinical Knowledge Summaries
British National Formulary (BNF) British National Formulary
British National Formulary for Children (BNFC) British National Formulary for Children
Life sciences
Library and knowledge services

What NICE does
Implementing NICE guidance
Get involved
About us
Careers
News, blogs and podcasts
Newsletters and alerts
Contact us
Leave feedback
Reusing our content
NICE UK Open Content Licence
Syndicate our content
Events

Facebook
X
YouTube
LinkedIn

Accessibility
Freedom of information
Glossary
Terms and conditions
Privacy notice
Cookies

© NICE 2026. All rights reserved. Subject to Notice of rights.